Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent® PC

MINNEAPOLIS, Dec. 6, 2017 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), announced today that Palmetto GBA, LLC, a Medicare Administrative Contractor serving approximately 4.5 million lives, has extended its coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) to allow patients with overactive bladder symptoms to receive ongoing maintenance treatments for up to three years. Patients with Medicare coverage in North Carolina, South Carolina, most of Virginia and West Virginia can continue to receive the benefits of PTNS therapy delivered by Cogentix Medical's Urgent PC Neuromodulation System for their overactive bladder (OAB) symptoms for an additional year.

"On behalf of the many overactive bladder patients who can benefit from Urgent PC's therapeutic benefits, we applaud Palmetto's decision to extend its coverage policy for PTNS maintenance treatments from two to three years," said Darin Hammers, President and CEO of Cogentix Medical.  "We believe this update underscores the value of Urgent PC as a long-term treatment option for an indication that has substantial unmet clinical need."

A low-risk, office-based therapy for overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence, Urgent PC is a recommended therapy within the American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction  (AUA/SUFU) OAB diagnosis and treatment guidelines.  Dr. Scott MacDiarmid, a urologist specializing in treating patients with OAB based in Greensboro, NC, stated, "Our office and, more importantly, our patients, were very excited regarding the recent decision by Palmetto to extend their coverage for PTNS. PTNS is a very important therapy for overactive bladder and it plays an integral role in helping us deliver excellence to our patients."

Urgent PC is a recommended third-line treatment in the AUA/SUFU guidelines for patients who have not met their treatment goals with behavioral therapies or bladder medications. Up to 80% of patients have symptom improvement during the initial 12 Urgent PC treatments and the majority of these patients are able to maintain the results long-term with monthly treatments.

For more detailed information about the extended coverage for PTNS, please visit the CMS website at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33443.

About Overactive Bladder

It is estimated that 42 million people in the United States alone have OAB, of which approximately 38 million remain untreated or undertreated. OAB occurs when bladder muscles become overly sensitive or overactive, which typically results from damage to the nervous system or to the nerves and muscles associated with bladder contractility. Symptoms of OAB include urinary urgency, urinary frequency or urge incontinence.

About Cogentix Medical

Cogentix Medical, Inc., is a global medical device company. We design, develop, manufacture and market products for flexible endoscopy with our unique PrimeSighttm product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier providing users with efficient and cost-effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent^® PC Neuromodulation System, an FDA-cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. We are is headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, For more information on Cogentix Medical and our products, please visit us at www.cogentixmedical.com.

SOURCE Cogentix Medical, Inc.